View Older Stories
-
William Blair on argenx SE (ARGX): 'we believe there are opportunities for further share upside'
-
4Q25/2026 Biotech Earnings Preview: RBC
-
H.C. Wainwright Reiterates Buy Rating on argenx SE (ARGX)
-
TD Cowen: 'we are confident that this leadership transition is designed to support argenx’s next phase of growth'
-
Piper Sandler Highlights Top Picks in the Biopharma 2026 Preview Note
-
BofA: 'Top SMid Biotech Picks Argenx, KalVista, Ocular, and Vertex'
-
argenx SE (ARGX) PT Raised to $1,006 at BofA Securities, 'remains one of our top picks for 2026'
-
Baird Downgrades argenx SE (ARGX) to Neutral
-
'argenx SE (ARGX) Is One Of Our Top Picks For 2026'; PT Raised at RBC Capital
-
Jefferies Reiterates Buy Rating on argenx SE (ARGX)
-
Guggenheim on argenx SE (ARGX): 'Long-term Growth Thesis Intact'
-
BofA Securities on argenx SE (ARGX): '2026 remains a catalyst-rich year'
-
argenx discontinues thyroid eye disease studies after futility analysis
-
argenx SE (ARGX) PT Raised to $1,248 at Stifel: Vyvgart Dominates MG Market
-
argenx SE (ARGX) PT Raised to $910 at UBS
-
argenx (ARGX) 500 contracts of May 1100 calls trade
-
Wolfe Research Downgrades argenx SE (ARGX) to Peerperform
-
argenx SE (ARGX) PT Raised to $1,040 at Oppenheimer
-
argenx SE (ARGX) PT Raised to $1,124 at Citi
-
'argenx SE (ARGX) Remains a Top Pick'; PT Raised to $930 at Piper Sandler
-
'argenx SE (ARGX) Remains a Top Pick'; PT Raised to $1,146 at TD Cowen
-
argenx (ARGX) Tops Q3 EPS by 74c; offers guidance
-
Piper Sandler: 'Biotech Has a Heartbeat: 17 Stocks to Own Through YE25'
-
Truist Securities: 'Is Biotech Back?!'
-
TD Cowen Reiterates Buy Rating on argenx SE (ARGX)
-
RBC Capital on argenx SE (ARGX): 'We Would Remain Buyers'
-
argenx SE (ARGX) PT Raised to $882 at Stifel
-
Oppenheimer Reiterates Outperform Rating on argenx SE (ARGX)
-
Truist Securities Reiterates Buy Rating on argenx SE (ARGX)
-
Truist Securities Assumes argenx SE (ARGX) at Buy
-
Deutsche Bank Downgrades argenx SE (ARGX:BB) (ARGX) to Hold
-
BofA Securities on argenx SE (ARGX): 'We see multiple shots on goal to expand the commercial opportunity with multiple phase 3 readouts for Vyvgart'
-
argenx SE (ARGX) PT Raised at Piper Sandler Following Successful Seronegative gMG Readout
-
JPMorgan Reiterates Overweight Rating on argenx SE (ARGX:BB) (ARGX)
-
argenx SE (ARGX) PT Raised to $808 at Jefferies
-
Oppenheimer Reiterates Outperform Rating on argenx SE (ARGX)
-
RBC on argenx SE (ARGX): 'Vyvgart Hits in snMG, TAM Likely to Be Expanded by an Additional 11k Patients'
-
RBC Capital Starts argenx SE (ARGX) at Outperform
-
argenx SE (ARGX:BB) (ARGX) PT Raised to EUR655 at Deutsche Bank
-
argenx SE (ARGX) PT Raised to $1,070 at Guggenheim
-
argenx SE (ARGX) PT Raised to $796 at Scotiabank
-
argenx SE (ARGX) PT Raised to $774 at H.C. Wainwright
-
argenx SE (ARGX) PT Raised to $778 at Oppenheimer
-
argenx SE (ARGX) PT Raised to $880 at BofA Securities
-
argenx (ARGX) Reports Q2 EPS of $6.32
-
argenx (ARGX) Added to BofA US 1 List
-
15 names that Morgan Stanley’s analysts expect to move meaningfully on earnings
-
argenx SE (ARGX) PT Raised to $829 at BofA Securities
-
Morgan Stanley Assumes argenx SE (ARGX) at Overweight
-
H.C. Wainwright Reiterates Buy Rating on argenx SE (ARGX)

